Efficacy and safety of recombinant human adenovirus-p53 injection combined with chemoradiotherapy in the treatment of locally advanced cervical cancer
Objective To investigate the efficacy and safety of recombinant human adenovirus-p53(rhAd-p53)injec-tion combined with chemoradiotherapy in the treatment of locally advanced cervical cancer(LACC).Methods LACC patients admitted to Jinhua Central Hospital from 2019 to 2021 were randomly divided into experimental group and control group.The control group was treated with chemoradiotherapy alone,and the experimental group was treated with rhAd-p53 combined with chemoradiotherapy.Serum tumor markers,mucin 1(MUC-1)and IL-33 were measured before and after treatment.The short term efficacy,long term survival prognosis,various indicators and the occurrence of adverse reactions were compared be-tween the two groups.Results A total of 120 LACC patients were included,with 60 patients in each group.The objective re-sponse rate in the experimental group was 88.3%,which was higher than that of the control group(70.0%)(P<0.05).The 3-year PFS rate in the experimental group was 74.0%,which was significantly higher than that of the control group(51.8%)(P<0.05).There was no significant difference in 3-year OS rate between the two groups(83.2%vs 69.7%,P>0.05).Com-pared with the control group,the levels of serum carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC),tumor-specific growth factor(TSGF),MUC-1 and IL-33 in the experimental group were lower(P<0.05)after treatment.There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion rhAd-p53 injection combined with chemoradiotherapy in the treatment of LACC patients can obtain better curative effect,and can effec-tively reduce serum tumor markers and IL-33,MUC-1 levels,which can benefit patients'long-term survival without increasing adverse reactions.
recombinant human adenovirus-p53locally advanced cervical cancermucin 1interleukin-33
NETL
NSTL
万方数据
